Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression
- PMID: 2142113
- DOI: 10.1016/0016-5085(90)91015-x
Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression
Abstract
The optimal degree and duration of suppression of gastric acidity required for the healing of peptic ulcers has never been established. Although very potent inhibitors of acid secretion are now available, the need for this degree of suppression has not been shown, and there is a possibility of adverse effects because of pronounced acid inhibition. Therefore, a model has been constructed that defines the relationship between duodenal ulcer healing and antisecretory therapy. Acid suppression data were obtained directly from investigators as raw data from 24-hour studies of acid secretion. Twenty-one experiments from seven investigators provided 490 24-hour studies using 19 different treatment regimens. Healing data were collected from a metaanalysis of published clinical trials of duodenal ulcer healing. A total of 144 published trials in 14,208 patients provided healing data at several endoscopic endpoints for the 19 drug regimens for which acidity data were provided. Weighted least-squares polynomial regression analysis was used to define those parameters of antisecretory therapy that contributed most to duodenal ulcer healing and to define the shape of the response surface. A highly significant correlation (r = 0.9814) was found between healing and the degree of acid suppression, the duration of acid suppression, and the length of therapy. The shape of the contour expression this relationship shows that healing increases as the duration of suppression increases and as gastric pH increases. However, suppression that increased pH beyond 3.0 was not found to increase ulcer healing further. It is concluded that a longer duration of antisecretory effect and/or a longer duration of therapy are of greater importance than potency for duodenal ulcer healing.
Comment in
-
Relationship between ulcer healing and acid suppression.Gastroenterology. 1991 May;100(5 Pt 1):1482-3. Gastroenterology. 1991. PMID: 2013398 No abstract available.
Similar articles
-
Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.Gut. 1987 Sep;28(9):1120-7. doi: 10.1136/gut.28.9.1120. Gut. 1987. PMID: 2890561 Free PMC article. Clinical Trial.
-
Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease.Scand J Gastroenterol Suppl. 1994;201:79-82. doi: 10.3109/00365529409105369. Scand J Gastroenterol Suppl. 1994. PMID: 8047830 Review.
-
The relationship between suppression of acidity and gastric ulcer healing rates.Aliment Pharmacol Ther. 1990 Feb;4(1):25-33. doi: 10.1111/j.1365-2036.1990.tb00445.x. Aliment Pharmacol Ther. 1990. PMID: 2151756
-
Optimizing acid suppression for treatment of acid-related diseases.Dig Dis Sci. 1995 Feb;40(2 Suppl):24S-49S. doi: 10.1007/BF02214870. Dig Dis Sci. 1995. PMID: 7859582 Review.
-
Relationship between inhibition of acid secretion and healing of peptic ulcers.Scand J Gastroenterol Suppl. 1989;166:43-7; discussion 74-5. doi: 10.3109/00365528909091243. Scand J Gastroenterol Suppl. 1989. PMID: 2690331 Review.
Cited by
-
Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy-a proof of concept analysis.J Drug Assess. 2014 Feb 17;3(1):20-7. doi: 10.3109/21556660.2014.895371. eCollection 2014. J Drug Assess. 2014. PMID: 27536450 Free PMC article.
-
Tolerance to oral H2-receptor antagonists.Dig Dis Sci. 1990 Aug;35(8):976-83. doi: 10.1007/BF01537246. Dig Dis Sci. 1990. PMID: 1974493 Clinical Trial.
-
Mealtime versus nighttime acid inhibition. A clinical pharmacological study with ranitidine.Dig Dis Sci. 1992 Sep;37(9):1368-72. doi: 10.1007/BF01296005. Dig Dis Sci. 1992. PMID: 1505287 Clinical Trial.
-
Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.Dig Dis Sci. 2005 Jul;50(7):1202-6. doi: 10.1007/s10620-005-2760-0. Dig Dis Sci. 2005. PMID: 16047460 Clinical Trial.
-
Efficacy of famotidine for omeprazole-refractory gastric ulcer.Dig Dis Sci. 1993 Mar;38(3):573-5. doi: 10.1007/BF01316518. Dig Dis Sci. 1993. PMID: 8444090 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical